mph Bangladesh

Frusemide (Furosemide)

(froo se mide) / (fyoor oh' se mide)

PCaution when used during lactation / LCaution when used during lactation : Caution - pregnancy &  lactation (breast feeding)

Molecule Info


Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs.

Indication(s) & Dosage

Furosemide is a potent diuretic with rapid action.

Furosemide tablets are indicated for:

- The treatment of fluid retention associated with heart failure, including left ventricular failure, cirrhosis of the liver and renal disease, including nephrotic syndrome.

- The treatment of mild to moderate hypertension when brisk diuretic response is required. Alone or in combination with other anti-hypertensive agents in the treatment of more severe cases.

Adult: 40-80 mg orally daily, alone or in conjunction with other antihypertensives. 
Oedema associated with heart failure
Adult: Initially, 20 mg orally daily or 40 mg every other day for mild cases, or 40 mg once daily adjusted according to response. In some cases, 80 mg or more daily as a single dose or in 2 divided doses may be required. Max: 600 mg daily in severe cases.
Child: 1-3 mg/kg orally daily. Max: 40 mg daily. 
Oedema associated with heart failure
Adult: 20-50 mg IM or slow IV Inj increased by 20-mg increments every 2 hr. Doses >50 mg must be given as IV infusion.
Child: 0.5-1.5 mg/kg daily. Max: 20 mg daily.
Pulmonary oedema
Adult: 40 mg via slow inj. If no adequate response within 1 hr, a further 80 mg may be given via infusion. 
Oliguria in acute or chronic renal failure
Adult: GFR: 5-20 ml/min: 250 mg diluted to 250 ml in a suitable diluent to be infused over 1 hr. If urine output is insufficient within the next hr, may follow by 500 mg added to an appropriate infusion fluid to be infused over 2 hr, total volume depends on the patient's state of hydration. If urine output is still unsatisfactory within 1 hr after the 2nd infusion then a 3rd dose of 1 g may be infused over 4 hr. Rate of infusion: <4 mg/min. For patients with significant fluid overload, inj may be given without dilution directly into the vein, rate of admin <4 mg/min. Patients who do not respond to a dose of 1 g may need dialysis. If the response is satisfactory, the effective dose (of up to 1 g) may be repeated every 24 hr. Subsequently, adjust dose according to patient's response.

Administration May be taken with or without food. May be taken w/ meals to reduce GI discomfort.

Overdose can cause massive diuresis resulting in dehydration, volume depletion and electrolyte disturbances with consequent hypotension and cardiac toxicity. The clinical picture in acute or chronic overdose depends primarily on the extent and consequences of electrolyte and fluid loss, e.g. hypovolaemia, dehydration, haemoconcentration, cardiac arrhythmias due to excessive diuresis. Symptoms of these disturbances include severe hypotension (progressing to shock), acute renal failure, thrombosis, delirious states, flaccid paralysis, apathy and confusion.High doses have the potential to cause transient deafness and may precipitate gout (disturbed uric acid secretion).


- Benefits of gastric decontamination are uncertain. In patients presenting within 1 hour of ingestion, consider activated charcoal (50g for adults: 1g/kg for children)

- Observe for a minimum of 4 hours - monitor pulse and blood pressure.

- Treat hypotension and dehydration with appropriate IV fluids

- Monitor urinary output and serum electrolytes (including chloride and bicarbonate). Correct electrolyte imbalances. Monitor 12 lead ECG in patients with significant electrolyte disturbances.


- Hypersensitivity to furosemide, amiloride, sulphonamides or sulphonamide derivatives, and/or any of the excipients of the product.

- Hypovolaemia and dehydration (with or without accompanying hypotension)

- Severe hypokalaemia: severe hyponatraemia.

- Comatose or pre-comatose states associated with hepatic cirrhosis.

- Anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma

- Impaired renal function with a creatinine clearance below 30ml/min per 1.73 mbody surface area.

- Addison's disease.

- Children and adolescents under 18 years of age (safety in this age group has not yet been established).

- Digitalis intoxication.

- Concomitant potassium supplements or potassium sparing diuretics.

- Porphyria

- Breast-feeding women.

Special Precautions

Conditions requiring correction before furosemide is started

- Hypotension.

- Hypovolaemia.

- Severe electrolyte disturbances - particularly hypokalaemia, hyponatraemia and acid-base disturbances.

Furosemide is not recommended

- In patients at high risk for radiocontrast nephropathy - it should not be used for diuresis as part of the preventative measures against radiocontrast-induced nephropathy.

- In patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Particular caution and/or dose reduction required:

- elderly patients (lower initial dose as particularly susceptible to side-effects)

- difficulty with micturition including prostatic hypertrophy (increased risk of urinary retention: consider lower dose). Closely monitor patients with partial occlusion of the urinary tract

- diabetes mellitus (latent diabetes may become overt: insulin requirements in established diabetes may increase: stop furosemide before a glucose tolerance test)

- pregnancy

- gout (furosemide may raise uric acid levels/precipitate gout)

- patients with hepatorenal syndrome

- impaired hepatic function

- impaired renal function

- adrenal disease

- hypoproteinaemia e.g. nephrotic syndrome (effect of furosemide may be impaired and its ototoxicity potentiated - cautious dose titration required).

- acute hypercalcaemia (dehydration results from vomiting and diuresis - correct before giving furosemide). Treatment of hypercalcaemia with a high dose of furosemide results in fluid and electrolyte depletion - meticulous fluid replacement and correction of electrolyte required.

- Patients who are at risk from a pronounced fall in blood pressure

- premature infants (possible development nephrocalcinosis/nephrolithiasis; renal function must be monitored and renal ultrasonography performed).

Avoidance with other medicines

- concurrent NSAIDs should be avoided - if not possible diuretic effect of furosemide may be attenuated

- ACE-inhibitors & Angiotensin II receptor antagonists - severe hypotension may occur - dose of furosemide should be reduced/stopped (3 days) before starting or increasing the dose of these

Laboratory monitoring requirements:

- Serum sodium

Particularly in the elderly or in patients liable to electrolyte deficiency

- Serum potassium

The possibility of hypokalaemia should be taken into account, in particular in patients with cirrhosis of the liver, those receiving concomitant treatment with corticosteroids, those with an unbalanced diet and those who abuse laxatives. Regular monitoring of the potassium, and if necessary treatment with a potassium supplement, is recommended in all cases, but is essential at higher doses and in patients with impaired renal function. It is especially important in the event of concomitant treatment with digoxin, as potassium deficiency can trigger or exacerbate the symptoms of digitalis intoxication. A potassium-rich diet is recommended during long-term use.

Frequent checks of the serum potassium are necessary in patients with impaired renal function and creatinine clearance below 60ml/min per 1.73m2 body surface area as well as in cases where furosemide is taken in combination with certain other drugs which may lead to an increase in potassium levels (see section 4.5 & refer to section 4.8 for details of electrolyte and metabolic abnormalities)

- Renal function

Frequent BUN in first few months of treatment, periodically thereafter. Long-term/high-dose BUN should regularly be measured. Marked diuresis can cause reversible impairment of kidney function in patients with renal dysfunction. Adequate fluid intake is necessary in such patients. Serum creatinine and urea levels tend to rise during treatment

- Glucose

Adverse effect on carbohydrate metabolism - exacerbation of existing carbohydrate intolerance or diabetes mellitus. Regular monitoring of blood glucose levels is desirable.

- Other electrolytes

Patients with hepatic failure/alcoholic cirrhosis are particularly at risk of hypomagnesia (as well as hypokalaemia). During long-term therapy (especially at high doses) magnesium, calcium, chloride, bicarbonate and uric acid should be regularly measured.

Clinical monitoring requirements:

Regular monitoring for

- blood dyscrasias. If these occur, stop furosemide immediately

- liver damage

- idiosyncratic reactions

Other alterations in lab values

- Serum cholesterol and triglycerides may rise but usually return to normal within 6 months of starting furosemide

Concomitant use with risperidone

In risperidone placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89 years, range 75-97 years) when compared to patients treated with risperidone alone (3.1%; mean age 84 years, range 70-96 years) or furosemide alone (4.1%; mean age 80 years, range 67-90 years). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.

No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be avoided in elderly patients with dementia.

Adverse Drug Reaction(s)

Undesirable effects can occur with the following frequencies: very common (> 1/10), common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (> 1/10,000, < 1,000) and very rare (< 1/10,000, including isolated reports).

Blood and lymphatic system disorders:


- thrombocytopenia


- Eosinophilia

- Leukopenia

- Bone marrow depression (necessitates withdrawal of treatment). The haemopoietic status should be therefore be regularly monitored.

Very Rare:

- aplastic anaemia or haemolytic anaemia

- agranulocytosis

Nervous system disorders


- paraesthesia

- hyperosmolar coma

Endocrine disorder

Glucose tolerance may decrease with furosemide. In patients with diabetes mellitus this may lead to a deterioration of metabolic control; latent diabetes mellitus may become manifest. Insulin requirements of diabetic patients may increase.

Eye disorders

Uncommon: visual disturbance

Ear and labyrinth disorders

Hearing disorders and tinnitus, although usually transitory, may occur in rare cases, particularly in patients with renal failure, hypoproteinaemia (e.g. in nephritic syndrome) and/or when intravenons furosemide has been given too rapidly.

Cardiac disorders

Uncommon: Cardiac arrhythmias

Furosemide may cause a reduction in blood pressure which, if pronounced may cause signs and symptoms such as impairment of concentration and reactions, light headedness, sensations of pressure in the head, headache, dizziness, drowsiness, weakness, disorders of vision, dry mouth, orthostatic intolerance.

Hepatobiliary disorders

In isolated cases, intrahepatic cholestasis, an increase in liver transaminases or acute pancreatitis may develop.

Hepatic encephalopathy in patients with hepatocellular insufficiency may occur.

Vascular Disorder:


- vasculitis

Skin and subcutaneous tissue disorders


- Photosensitivity


Skin and mucous membrane reactions may occasionally occur, e.g. itching, urticaria, other rashes or bullous lesions, fever, hypersensitivity to light, exsudative erythema multiforme (Lyell's syndrome and Stevens-Johnson syndrome), bullous exanthema, exfoliative dermatitis, purpura, AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug rash with eosinophilia and systemic symptoms)..

Metabolism and nutrition disorders

As with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis after prolonged therapy. Furosemide leads to increased excretion of sodium and chloride and consequently increase excretion of water. In addition, excretion of other electrolytes (in particular potassium, calcium and magnesium) is increased.

Metabolic acidosis can also occur. The risk of this abnormality increases at higher dosages and is influenced by the underlying disorder (e.g. cirrhosis of the liver, heart failure), concomitant medication and diet.

Symptomatic electrolyte disturbances and metabolic alkalosis may develop in the form of a gradually increasing electrolyte deficit or e.g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses,

Symptoms of electrolyte imbalance depend on the type of disturbance:

Sodium deficiency can occur; this can manifest itself in the form of confusion, muscle cramps, muscle weakness, loss of appetite, dizziness, drowsiness and vomiting.

Potassium deficiency manifests itself in neuromuscular symptoms (muscular weakness, paralysis), intestinal symptoms (vomiting, constipation, meterorism), renal symptoms (polyuria) or cardiac symptoms. Severe potassium depletion can result in paralytic ileus or confusion, which can result in coma.

Magnesium and calcium deficiency result very rarely in tetany and heart rhythm disturbances.

Serum calcium levels may be reduced; in very rare cases tetany has been observed.

Nephrocalcinosis/Nephrolithiasis has been reported in premature infants.

Serum cholesterol (reduction of serum HDL-cholesterol, elevation of serum LDL-cholesterol) and triglyceride levels may rise during furosemide treatment. During long term therapy they will usually return to normal within six months,

As with other diuretics, treatment with furosemide may lead to transitory increase in blood creatinine and urea levels. Serum levels of uric acid may increase and attacks of gout may occur.

The diuretic action of furosemide may lead to or contribute to hypovolaemia and dehydration, especially in elderly patients. Severe fluid depletion may lead to haemoconcentration with a tendency for thromboses to develop.

General disorders and administration site conditions

Uncommon: Fatigue


- Severe anaphylactic or anaphylactoid reactions (e.g. with shock) occur rarely.

- fever

- Malaise

Gastrointestinal disorders

Uncommon: dry mouth, thirst, nausea, bowel motility disturbances, vomiting, diarrhea, constipation.

Gastro-intestinal disorders such as nausea, or gastric upset (vomiting or diarrhoea) and constipation may occur but not usually severe enough to necessitate withdrawal of treatment.


Acute Pancreatitis

Renal and urinary disorders


- serum creatinine and urea levels can be temporarily elevated during treatment with furosemide.


- interstitial nephritis, acute renal failure.

Increased urine production, urinary incontinence, can be caused or symptoms can be exacerbated in patients with urinary tract obstruction. Acute urine retention, possibly accompanied by complications, can occur for example in patients with bladder disorders, prostatic hyperplasia or narrowing of the urethra.

Pregnancy, puerperium and perinatal conditions

In premature infants with respiratory distress syndrome, administration of Furosemide Accord Tablets in the initial weeks after birth entails an increased risk of a persistent patent ductus arteriosus.

In premature infants, furosemide can be precipitated as nephrocalcinosis/kidney stones.

Rare complications may include minor psychiatric disturbances.

Drug Interactions

General- The dosage of concurrently administered cardiac glycosides, diuretics, anti-hypertensive agents, or other drugs with blood-pressure-lowering potential may require adjustment as a more pronounced fall in blood pressure must be anticipated if given concomitantly with furosemide.

The toxic effects of nephrotoxic drugs may be increased by concomitant administration of potent diuretics such as furosemide.

Some electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome).

Antihypertensives - enhanced hypotensive effect possible with all types. Concurrent use with ACE inhibitors or Angiotensin II receptor antagonists can result in marked falls in blood pressure, furosemide should be stopped or the dose reduced before starting an ACE-inhibitor or Angiotensin II receptor antagonists

Antipsychotics - furosemide-induced hypokalaemia increases the risk of cardiac toxicity. Avoid concurrent use with pimozide. Increased risk of ventricular arrhythmias with amisulpride or sertindole. Enhanced hypotensive effect with phenothiazines.

When administering risperidone, caution should be exercised and the risks and benefits of the combination or co-treatment with furosemide or with other potent diuretics should be considered prior to the decision to use. See section 4.4 Special warnings and precautions for use regarding increased mortality in elderly patients with dementia concomitantly receiving risperidone.

Anti-arrhythmics (including amiodarone, disopyramide, flecanaide and sotalol) - risk of cardiac toxicity (because of furosemide-induced hypokalaemia). The effects of lidocaine, tocainide or mexiletine may be antagonised by furosemide.

Cardiac glycosides - hypokalaemia and electrolyte disturbances (including hypomagnesia) increase the risk of cardiac toxicity.

Drugs that prolong Q-T interval - increased risk of toxicity with furosemide-induced electrolyte disturbances

Vasodilators - enhanced hypotensive effect with moxisylyte (thymoxamine) or hydralazine

Other diuretics - profound diuresis possible when furosemide given with metolazone. Increased risk of hypokalaemia with thiazides. Contraindicated with potassium sparing diuretics (eg Amiloride spironolactone) - increased risk of hyperkalaemia

Renin inhibitors - aliskiren reduces plasma concentrations of furosemide

Nitrates - enhanced hypotensive effect

Lithium - In common with other diuretics, serum lithium levels may be increased when lithium is given concomitantly with furosemide, resulting in increased lithium toxicity, including increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels are carefully monitored and where necessary the lithium dosage is adjusted in patients receiving this combination.

Chelating agents - sucralfate may decrease the gastro-intestinal absorption of furosemide - the 2 drugs should be taken at least 2 hours apart

NSAIDs - increased risk of nephrotoxicity. Indometacin and ketorolac may antagonise the effects of furosemide (avoid if possible see section 4.4)

Salicylates - effects may be potentiated by furosemide. Salycylic toxicity may be increased by furosemide

Antibiotics - increased risk of ototoxicity with aminoglycosides, polymixins or vancomycin - only use concurrently if compelling reasons. Increased risk of nephrotoxicity with aminoglycosides or cefaloridine. Furosemide can decrease vancomycin serum levels after cardiac surgery. Increased risk of hyponatraemia with trimethoprim. Impairment of renal function may develop in patients receiving concurrent treatment with furosemide and high doses of certain cephalosporins.

Antidepressants - enhanced hypotensive effect with MAOIs. Increased risk of postural hypotension with TCAs (tricyclic antidepressants). Increased risk of hypokalaemia with reboxetine

Antidiabetics - hypoglycaemic effects antagonised by furosemide

Antiepileptics - increased risk of hyponatraemia with carbamazepine. Diuretic effect reduced by phenytoin.

Antihistamines - hypokalaemia with increased risk of cardiac toxicity

Antifungals - increased risk of hypokalaemia and nephrotoxicity with amphoterecin

Anxiolytics and hypnotics - enhanced hypotensive effect. Chloral or triclorfos may displace thyroid hormone from binding site.

CNS stimulants (drugs used for ADHD) - hypokalaemia increases the risk of ventricular arrhythmias

Corticosteroids - diuretic effect anatgonised (sodium retention) and increased risk of hypokalaemia

Glychyrrizin - (contained in liquorice) may increase the risk of developing hypokalaemia.

Carbenoxolone -may increase the risk of developing hypokalaemia

Cytotoxics - increased risk of nephrotoxicity and ototoxicity with platinum compounds/cisplatin. Nephrotoxicity of cisplatin may be enhanced if furosemide is not given in low doses (e.g. 40 mg in patients with normal renal function) and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

Anti-metabolites - effects of furosemide may be reduced by methotrexate and furosemide may reduce renal clearance of methotrexate

Potassium salts - contraindicated - increased risk of hyperkalaemia

Dopaminergics - enhanced hypotensive effect with levodopa.

Immunomodulators - enhanced hypotensive effect with aldesleukin. Increased risk of hyperkalaemia with ciclosprin and tacrolimus. Increased risk of gouty arthritis with ciclosporin

Muscle relaxants - enhanced hypotensive effect with baclofen or tizanidine. Increased effect of curare-like muscle relaxants

Oestrogens - diuretic effect antagonised

Progestogens (drosperidone) - increased risk of hyperkalaemia

Prostaglandins - enhanced hypotensive effect with alprostadil

Sympathomimetics - increased risk of hypokalaemia with high doses of beta2 sympathomimetics

Theophylline - enhanced hypotensive effect

Probenecid - effects of furosemide may be reduced by probenecid and furosemide may reduce renal clearance of probenecid.

Anaesthetic agents - general anaesthetic agents may enhance the hypotensive effects of furosemide. The effects of curare may be enhanced by furosemide.

Alcohol - enhanced hypotensive effect

Laxative abuse - increases the risk of potassium loss

Others: Concomitant administration of aminoglutethimide may increase the risk of hyponatraemia.

Pregnancy Category (FDA)

Pregnancy Category C

There is clinical evidence of safety of the drug in the third trimester of human pregnancy & furosemide has been given after the first trimester of pregnancy for oedema, hypertension and toxaemia of pregnancy without causing fetal or newborn adverse effects. However, furosemide crosses the placental barrier and should not be given during pregnancy unless there are compelling medical reasons. It should only be used for the pathological causes of oedema which are not directly or indirectly linked to the pregnancy. The treatment with diuretics of oedema and hypertension caused by pregnancy is undesirable because placental perfusion can be reduced, so, if used, monitoring of fetal growth is required.

Category DIf used in gestational HTN. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).


Furosemide is contraindicated as it passes into breast milk and may inhibit lactation.

Storage Intravenous: Store at 15-30°C. Oral: Store at 15-30°C. Parenteral: Store at 15-30°C.

The evidence from many experimental studies suggests that furosemide acts along the entire nephron with the exception of the distal exchange site. The main effect is on the ascending limb of the loop of Henley with a complex effect on renal circulation. Blood-flow is diverted from the juxta-medullary region to the outer cortex.

The principle renal action of furosemide is to inhibit active chloride transport in the thick ascending limb. Re-absorption of sodium, chloride from the nephron is reduced hypotonic or isotonic urine produced.

It has been established that prostaglandin (PG) biosynthesis the renin-angiotensin system are affected by furosemide administration and that furosemide alters the renal permeability of the glomerulus to serum proteins.

Absorption: Fairly rapidly absorbed from the GI tract (oral).
Distribution: Crosses the placenta and enters breast milk. Protein-binding: 99%.
Excretion: Via urine (as unchanged); 2 hr (elimination half-life), may be prolonged in neonates and renal and hepatic impairment.

Approximately 65% of the dose is absorbed after oral administration. The plasma half-life is biphasic with a terminal elimination phase of about 1½ hours. Furosemide is up to 99% bound to plasma proteins and is mainly excreted in the urine, largely unchanged, but also excreted in the bile, non-renal elimination being considerably increased in renal failure. Furosemide crosses the placental barrier and is excreted in the milk.

Furosemide is a weak carboxylic acid which exists mainly in the dissociated form in the gastrointestinal tract. Furosemide is rapidly but incompletely absorbed (60-70%) on oral administration and its effect is largely over within 4 hours. The optimal absorption site is the upper duodenum at pH 5.0. Regardless of route of administration 69-97% of activity from a radio-labelled dose is excreted in the first 4 hours after the drug is given. Furosemide is bound to plasma albumin and little biotransformation takes place. Furosemide is mainly eliminated via the kidneys (80-90%); a small fraction of the dose undergoes biliary elimination and 10-15% of the activity can be recovered from the faeces.

In renal/ hepatic impairment

Where liver disease is present, biliary elimination is reduced up to 50%. Renal impairment has little effect on the elimination rate of furosemide, but less than 20% residual renal function increases the elimination time.

The elderly

The elimination of furosemide is delayed in the elderly where a certain degree of renal impairment is present.

ATC Classification C03CA01 - furosemide; belongs to the class of high-ceiling sulfonamide diuretics. Used to promote excretion of urine.

Brand/Product Info

Total Products : 12            
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
FRUDEMA Pacific Pharmaceuticals Ltd. Frusemide BP 40mg Tablet 100's: 53.00 MRP
FRUSIN Opsonin Pharma Limited Frusemide BP 40mg Tablet 100's: 50.00 MRP
FRUSIN Injection Opsonin Pharma Limited Frusemide BP 20mg/2ml Injection 25's: 82.50 MRP
FRUSIN Syrup Opsonin Pharma Limited Frusemide BP 20mg/5ml Syrup 60ml: 85.00 MRP
FUSID 40 Square Pharmaceuticals Ltd. Furosemide 40mg Tablet 10x20's: 128.00 MRP
FUSID INJ Square Pharmaceuticals Ltd. Furosemide 20mg/2 ml IM/IV Injection 2x5's: 80.30 MRP
G-FRUSEMIDE Gonoshasthaya Pharmaceuticals Ltd Frusemide BP 40mg Tablet 100's: 52.00 MRP
G-FRUSEMIDE Injection Gonoshasthaya Pharmaceuticals Ltd Frusemide BP 20mg/2ml Injection 2ml amp x 25's: 75.50 MRP
LASIX Sanofi Frusemide BP 40mg Tablet 100's: 64.24 MRP
LASIX Injection Sanofi Frusemide BP 20mg/2ml Injection 2ml amp x 25's: 200.00 MRP
TROFURIT Ambee Pharmaceuticals Ltd. Frusemide BP 40mg Tablet 100's: 53.00 MRP
TROFURIT Injection Ambee Pharmaceuticals Ltd. Frusemide BP 20mg/2ml Injection 10 amps: 35.30 MRP

Gen. MedInfo

Why is this medication prescribed?

Furosemide, a 'water pill,' is used to reduce the swelling and fluid retention caused by various medical problems, including heart or liver disease. It is also used to treat high blood pressure. It causes the kidneys to get rid of unneeded water and salt from the body into the urine.

This medicine is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

How should this medicine be used?

Furosemide comes as a tablet and liquid to take by mouth. It usually is taken once a day in the morning or twice a day in the morning and afternoon. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take furosemide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Furosemide controls high blood pressure but does not cure it. Continue to take furosemide even if you feel well. Do not stop taking furosemide without talking to your doctor.

What special precautions should I follow?

Before taking furosemide,

  • tell your doctor if you are allergic to furosemide, sulfa drugs, or any other drugs.
  • tell your doctor what prescription and nonprescription medications you are taking, especially other medications for high blood pressure, aspirin, corticosteroids (e.g., prednisone), digoxin, indomethacin, lithium, medications for diabetes, probenecid, and vitamins. If you also are taking cholestyramine or colestipol, take it at least 1 hour after taking furosemide.
  • tell your doctor if you have or have ever had diabetes, gout, or kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. Do not breast-feed while taking this medicine. If you become pregnant while taking furosemide, call your doctor.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking furosemide.
  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Furosemide may make your skin sensitive to sunlight.

What special dietary instructions should I follow?

Follow your doctor's directions. They may include a daily exercise program and a low-sodium or low-salt diet, potassium supplements, and increased amounts of potassium-rich foods (e.g., bananas, prunes, raisins, and orange juice) in your diet.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Frequent urination may last for up to 6 hours after a dose and should decrease after you take furosemide for a few weeks. Tell your doctor if any of these symptoms are severe or do not go away:

  • muscle cramps

  • weakness

  • dizziness

  • confusion

  • thirst

  • upset stomach

  • vomiting

  • blurred vision

  • headache

  • restlessness

  • constipation

If you have any of the following symptoms, consult your doctor immediately:

  • fever

  • sore throat

  • ringing in the ears

  • unusual bleeding or bruising

  • loss of hearing

  • severe rash with peeling skin

  • difficulty breathing or swallowing

  • rapid, excessive weight loss

What should I know about storage and disposal of this medication?

Keep this medicine in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Throw away unused furosemide liquid after 60 days. Throw away any medicine that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medicine.

In case of emergency/overdose

In case of overdose, consult your doctor. If the victim has collapsed or is not breathing, consult local medical emergency services.

What other information should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to this medicine.

Do not let anyone else use your medication. If you still have symptoms and need further treatment, consult your doctor.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Ref:  U.S. National Library of Medicine.

 This information is provided for reference only and not a replacement for and should only be used in conjunction with full consultation with a registered medical practitioner. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, mph-bd shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.

 | See Brand Manufacturer's Prescribing Information | | Back to top |

Simple Breath Test Might Diagnose Heart Failure An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a...
Osteoporosis drug stops Breast cancer growth   News & Events News & Events     HIGHLIGHTS Osteoporosis drug stops growth of breast cancer...
Generic drug safety info loophole FDA plans to close generic drug safety info loophole The US Food and Drug Administration has announced plans to speed up the dissemination of...
Large trials unpublished   News & Events News & Events   HIGHLIGHTS Almost 1 in 3 of large clinical trials unpublished after...
TB activists boo Indian minister News & Events News & Events   HIGHLIGHTS TB activists at world conference boo Indian minister off...
Key bone marrow protein identified News & Events News & Events   HIGHLIGHTS Key bone marrow protein identified as potential new leukemia...